-
Pharmaceutical stocks plummeted. Hengrui, Mindray, Changchun Hi-tech, WuXi and others staged a battle royale!
Time of Update: 2021-09-05
On the whole, this performance is as stable as ever, but because of careful comparison, the company's operating income and main business gross profit margin are not as good as market expectations, plus the investment indicator-Hillhouse Capital reduced its holdings in the second quarter Half of the shares are regarded as a major negative .
-
Research progress in the development of long-acting technologies for protein and peptide drugs (Part 1)
Time of Update: 2021-09-05
To improve the stability of protein and peptide drugs, prolong the half-life in the body, and make it long-acting .
-
Rongchang Biotechnology is favored by American ADC giants!
Time of Update: 2021-09-05
Rongchang Bio-Vidicuzumab Research and Development ProgressIn the sci-tech innovation board prospectus, Rongchang Biological expects to complete the phase III confirmatory clinical trial of vedicitumumab for the treatment of gastric cancer in 2026, ensuring that it is fully approved for marketing .
-
Huabei Pharmaceutical's new rabies drug, omiltivizumab, has not been approved for large specifications
Time of Update: 2021-09-05
Article source: Medical Rubik's Cube InfoOn August 12, North China Pharmaceutical submitted a new class 1 recombinant human anti-rabies monoclonal antibody (ormutivimab) for the passive immunization of rabies virus-exposed patients.
-
Ma Yinglong Pharmaceutical Appoints Liu Pingan as Deputy General Manager
Time of Update: 2021-09-05
On August 20, Ma Yinglong Pharmaceutical issued an announcement stating that the company held the twelfth meeting of the tenth board of directors on August 19 and passed the "Proposal on the Appointment of Senior Executives .
Liu Ping’an was appointed as the company’s deputy general manager .
-
Venlafaxine Hydrochloride Sustained-Release Capsules, a subsidiary of Renfu Pharmaceutical, obtained FDA approval
Time of Update: 2021-09-05
On August 9, Renfu Medicine issued an announcement stating that its holding subsidiary, Yichang Renfu, had received the US FDA’s approval number for venlafaxine hydrochloride sustained-release capsules, which are suitable for various types of depression, including those accompanied by anxiety.
-
Jiangsu raises the per capita financial subsidy standard for resident medical insurance not less than 610 yuan per person per year
Time of Update: 2021-09-04
(Receptionist Wu Rui) Medical Network News on August 24, Jiangsu Provincial Medical Insurance Bureau announced that this year Jiangsu will continue to improve the level of funding for basic medical insurance for urban and rural residents, and consolidate and improve residents' medical insurance benefits .
-
Boehringer Ingelheim and Anritsu Xirong jointly developed EI-001 and completed clinical application
Time of Update: 2021-09-04
EI-001 antibodies are prepared by a single human B cells obtained technology, which is closely related to target the pathology of vitiligo, hepatitis B and the like .
-
Up to 1 billion!
Time of Update: 2021-09-04
Shanghai Jinmante Biological, a wholly-owned subsidiary of CSPC, will obtain the right to develop and commercialize KN026's breast and gastric cancer indications in Mainland China (excluding Hong Kong, Macau and Taiwan), and become the listing of KN026 in Mainland China.
-
North China Pharmaceutical’s penalty for the suspension of supply is a response from the Fermentation United Procurement Agency
Time of Update: 2021-09-04
Regarding North China Pharmaceutical’s breach of contract, the United Procurement Office has stated in its announcement on August 20 that the company’s ibuprofen sustained-release capsules selected in the third batch of nationally organized drug procurement failed to supply the agreed procurement volume in Shandong Province according to the agreement.
-
North China Pharmaceutical's "National Centralized Procurement Out of Stock" was included in the "List of Violations"
Time of Update: 2021-09-04
(hereinafter referred to as "Huabei Pharmaceutical"), the selected company in the third batch of nationally organized drug centralized procurement of ibuprofen sustained-release capsules, failed to supply the agreed procurement volume in Shandong Province according to the agreement.
-
The first generic drug outbreak!
Time of Update: 2021-09-04
It was approved for import in May 2017, and its domestic sales scale in 2020 Over 170 million yuan, there are currently 18 domestic companies submitting applications for the listing of the product under the new classification, of which Kelun is the first .
-
Bristol-Myers Squibb Opdivo receives FDA approval for adjuvant treatment of urothelial cancer
Time of Update: 2021-09-04
Based on CheckMate- As a result of the safety and effectiveness of 274, Opdivo provides a new FDA-approved therapy that can reduce the risk of disease recurrence or death, and may become a new standard of care for such patients .
-
Two senior managers of GlaxoSmithKline leave
Time of Update: 2021-09-04
The last working day is September 17, before the arrival of the new head of registration affairs, GSK vice president and GCI regional registration affairs The person in charge, Alexandra Kitashova, is temporarily under the escrow .
-
The Dilemma of Innovation: From the PD(L)1 track to see the innovation choices of Chinese local leading companies
Time of Update: 2021-09-04
Text | Yichun Yiqiu"Double reduction", "School District Housing Reform", "Clinical Value-Oriented Drug Development", "New Coronavirus Mutant". . . Under intensive regulation, the secondary market has
-
The global epidemic has repeated, and the price of Banlangen has risen again!
Time of Update: 2021-09-04
The production area is smooth, and the price is rising steadily Bozhou Market: Recently, Banlangen's supply has moved well in the market, and inventory has been effectively digested.
-
CDE Director Kong Fanpu: Innovative drug review set a new record, and the international drug review track accelerated
Time of Update: 2021-09-04
With the year-on-year increase in the number of drug registration application tasks and the high technical content of the declared varieties, the overall completion rate of the innovative drug-related tasks of the Center for Drug Evaluation exceeded 90% within the time limit .
-
Fosun Pharma Announces 2021 Interim Results, Innovation Results Continue to Land, International Operation Capability Further Improved
Time of Update: 2021-09-04
73%;· The joint venture Fosun Kate’s Yi Kai Da is the first CAR-T cell therapy product approved for marketing in China;· Fubitai® (mRNA Covid-19 vaccine, BNT162b2) was included in the government vaccination program in Hong Kong and Macau in the first half of the year; and it plans to supply 15 million doses of mRNA Covid-19 vaccine to Taiwan, China .
-
North China Pharmaceuticals has a lower limit!
Time of Update: 2021-09-04
It was once the cradle of the pharmaceutical industry in New China and was known as the “eldest son of medicine” of the Republic. North China Pharmaceuticals, one of the four major pharmaceutical fac
-
What kind of industry signal does Hengrui adjust its sales team to release?
Time of Update: 2021-09-04
Author: ProbioticsRecently, Hengrui Medicine held an extraordinary general meeting of shareholders. Hengrui Chairman Sun Piaoyang announced the abolition and adjustment plan for the sales team, which
